

FINANCIAL TEAR SHEET

Corporate Profile

Adaptimmune is a leader in the TCR T-cell therapy space focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets - whether intracellular or surface expressed - for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides in order to target and potentially destroy cancer cells in patients.

Our wholly-owned pipeline of SPEAR T-cell therapies and targets continues to evolve; SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we continue to build a pipeline of proprietary TCR therapeutic candidates: We have identified over 25 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs. We believe these research programs are relevant to a wide range of cancer indications.

We believe our approach will lead to SPEAR therapeutic candidates that have the potential to significantly impact cancer treatment and the clinical outcomes of patients with cancer.

Primary IR Contact

Investor Contact

Email:


IR@adaptimmune.com

Stock Performance

ADAP (AMERICAN DEPOSITARY SHARES)

| | |
|--------------------|-----------------------|
| Exchange | NASDAQ GS (US Dollar) |
| Price | \$8.62 |
| Change (%) | ▲ 0.12 (1.41%) |
| Volume | 44,399 |
| 52 Week Low | \$3.88 |
| Market Cap | \$4,778,014,339 |
| Rolling EPS | -0.75 |
| PE Ratio | 0 |
| Shares Outstanding | 562,119,334 |

Data as of 01/23/18 9:43 a.m. ET



Recent Headlines & Events

01/08/18

[Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose](#)

01/08/18

[Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company](#)

01/04/18

[Paul Stead Joins Adaptimmune as Vice President of Business Development](#)

There are currently no events scheduled.

SEC Filings

FILING DATE

FORM

Corporate Governance

[James Noble](#)

Chief Executive Officer

| | | | |
|----------|----------|--------------------------------------|--------------------------|
| 01/17/18 | <u>4</u> | <u>Adrian Rawcliffe</u> | Chief Financial Officer |
| 01/17/18 | <u>4</u> | <u>Helen Tayton-Martin, PhD, MBA</u> | Chief Operating Officer |
| 01/17/18 | <u>4</u> | <u>Rafael Amado, MD</u> | Chief Medical Officer |
| 01/17/18 | <u>4</u> | <u>Bent Jakobsen, PhD</u> | Scientific Co-Founder |
| 01/17/18 | <u>4</u> | <u>Gwendolyn Binder-Scholl, PhD</u> | Chief Technology Officer |

Data provided by Nasdaq. Minimum 15 minutes delayed.